CTRI/2011/05/001733已完成4 期
A Phase IV, Single Arm, Open label, Multi-Centric Study to Evaluate Efficacy, Safety and Tolerability of Anastrozole as an adjuvant to Paclitaxel for Postmenopausal Women with hormone-receptor positive metastatic Breast Cancer .
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Cipla Ltd
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Note: This trial do not have upper age limit for inclusion criteria.
- •1.A potential subject willing to give written informed consent on his own or legally acceptable representative (LAR) /Impartial witness in case of Illiterate subject and comply with all study procedures.
- •2.Female subjects entering the study should be greater than or equal to 45 Years of age.
- •3.Subjects entering the study should be Post-menopausal women, defined as:
- •a.Bilateral Surgical Oophorectomy or Amenorrhea greater than or equal to 5 years
- •b.Age greater than or equal to 45 years and Amenorrhea greater than or equal to 1 year
- •c.Chemotherapy induced Amenorrhea greater than or equal to 2 years
- •d.Radiotherapy induced Amenorrhea at least 3 months before.
- •4.Subjects participating in the study should be those with histologically or cytologically proven pathological diagnosis of Metastatic Breast Cancer
- •5.Subjects should have been proven Estrogen Receptor and/or Progesterone Receptor Positive (ER+/PR+).
- •6.Subjects entering the study should have a radiologically measurable disease
- •7.Subjects who have received adjuvant Tamoxifen are eligible, if progression has been established within 24 months since treatment start.
- •8.Subjects receiving Paclitaxel as first line of chemotherapy for advanced Metastatic Breast Cancer or Treatment-naive patients.
- •9.Subjects who have received previous treatment with targeted therapy are eligible, whereas subjects already receiving Anastrozole or other aromatase inhibitors should undergo a one month washout period prior to the start of study drug administration.
- •10.Subjects entering the study should have following Normal Hematological values (Hb greater than 9.0 gm/ dL, Platelet greater than or equal to 1, 00000/ cumm), Hepatic Profile (Bilurubin, Total Biluribin less than or equal to 1.5 times ULN, Alalnine Transaminase (ALT)less than or equal to 2.5 time ULN, Aspartate Transaminase (AST) less than or equal to 2.5 times ULN, Alkaline Phosphatase (ALP) less than 2.5 ULN,)) and Renal Functions (Serum Creatinine less than or equal to 1.5 times ULN).
- •11.Subjects entering the study should have an ECOG Performance Status of 0-2.
- •12.Subjects participating in the study should have a life expectancy of at least 6 months, or as per the investigators discretion.
排除标准
- •Note: This trial do not have upper age limit for exclusion criteria.
- •1. Subjects who are pre-menopausal women.
- •2.Subjects who have received previous hormone treatment with class of aromatase inhibitor or any other hormonal treatment within 1 month in metastatic disease.
- •3.Subjects who are negative for Estrogen Receptor and/or Progesterone Receptor (Negative ER- / PR status).
- •4.Subjects receiving Glucocorticoid therapy
- •5.Subjects with an increase in High Density Lipoprotein-Cholesterol (HDL-C).
- •6.Subjects with known Inflammatory breast cancer, refractory malignancy or metastasis in the central nervous system
- •7.Subjects with only bone metastasis.
- •8.Subjects with a non-measurable disease.
- •9.Subjects with known hypersensitivity to the study drug or to any of the excipients.
- •10.Subjects with secondary malignancy except for basal skin carcinoma or adequately treated cervical in-situ carcinoma
- •11.Subjects who have participated in any other investigational drug therapy within 1 month prior to the screening visit.
- •12.Subjects with any other severe concurrent disease, which in the judgment of the investigator would make the subject inappropriate for entry into this study.
研究者
相似试验
进行中（未招募）
4 期
A clinical trial to study effects of Denosumab in the Treatment of Postmenopausal Osteoporosis.CTRI/2023/05/052831Enzene Biosciences Limited
招募中
4 期
A study to evaluate the safety and efficacy of Bevacizumab in approved indications.CTRI/2017/12/010893Intas Pharmaceuticals Limited
已完成
4 期
A clinical trial to describe the safety of 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age.CTRI/2018/11/016324Pfizer Limited Subsidiary of Pfizer Inc100
已完成
4 期
The study is to check the safety and effectiveness of romiplostim in patients suffering from severe purple discoloration of skin due to low platelets.CTRI/2023/05/053181Alkem Laboratories Limited25
进行中（未招募）
1 期
A study on the immune response and safety of a vaccine against Neisseria meningitidis serogroup B infection in healthy infants from 2 months of ageHealthy volunteers (active immunization of infants against invasive meningococcal disease (IMD) due to N. meningitidis serogroup B infection).EUCTR2023-000764-58-Outside-EU/EEAGlaxoSmithKline Biologicals SA